本帖最后由 老马 于 2013-3-13 13:43 编辑 ( ]% A/ o' J+ c% L6 }7 D0 d
% F3 H( a5 h; ^, C- h. v# V3 Q* ?3 g
健择（吉西他滨）+顺铂+阿瓦斯汀
) @6 o! P" m4 C( j' n. t Gemzar +Cisplatin + Avastin& t# \; E$ G4 Y
http://annonc.oxfordjournals.org/content/21/9/1804.full
- k' d _# K4 m9 Q" ~Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) v0 m- q$ s+ L9 H- G) p
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% }3 Q( }7 e8 _2 t9 x, jResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. / |7 H* n. `9 O, y: n# l
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 242)
- P% ^+ M/ k$ M" c! H. o华为网盘附件：
. p8 K: [% {+ L: _' _$ \9 G# @. i【华为网盘】ava.JPG9 Q1 h. B Y8 n0 `! ]/ o$ W
|
显身卡
